Genetic therapies for cardiovascular diseases

Trends in Molecular Medicine

Volumn 11, Issue 5, 2005, Pages 240-250

  Melo, Luis G ^a,b   Pachori, Alok S ^b   Gnecchi, Massimiliano ^b   Dzau, Victor J ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADENOVIRUS VECTOR; ADENYLATE CYCLASE; ADENYLATE CYCLASE VI; ADRENOMEDULLIN; ANGIOGENIC FACTOR; ANTIANGINA PECTORIS AGENT; ANTIARRHYTHMIC AGENT; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIMITOTIC AGENT; ANTIOXIDANT; ANTISENSE OLIGODEOXYNUCLEOTIDE; ANTITHROMBOCYTIC AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN E; APTAMER; ATRIAL NATRIURETIC FACTOR; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CATALASE; COMPLEMENTARY DNA; COPPER ZINC SUPEROXIDE DISMUTASE; DRUG CARRIER; ENDOTHELIAL NITRIC OXIDE SYNTHASE; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; GLUTATHIONE PEROXIDASE; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; HEAT SHOCK PROTEIN 27; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEME OXYGENASE 1; HERPESVIRUS VECTOR; HUMAN ETHER A GO GO RELATED GENE POTASSIUM CHANNEL PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN ALPHA SUBUNIT; INTERCELLULAR ADHESION MOLECULE 1; KALLIKREIN; KININ; LENTIVIRUS VECTOR; LIPOSOME; LOW DENSITY LIPOPROTEIN RECEPTOR; MANGANESE SUPEROXIDE DISMUTASE; OLIGODEOXYNUCLEOTIDE; PARVOVIRUS VECTOR; PLASMID VECTOR; POTASSIUM CHANNEL AFFECTING AGENT; POTASSIUM CHANNEL HERG; POTASSIUM CHANNEL KIR2.1 PROTEIN; PROTEIN BCL 2; PROTEIN KINASE B; RETROVIRUS VECTOR; RIBOZYME; SARCOGLYCAN; SARCOGLYCAN DELTA; SARCOPLASMIC RETICULUM CALCIUM ATPASE 1; SARCOPLASMIC RETICULUM CALCIUM ATPASE 2A; SCATTER FACTOR; SUPEROXIDE DISMUTASE; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR E2F1; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VASCULOTROPIN C; VASODILATOR AGENT;

ACUTE HEART FAILURE; ACUTE HEART INFARCTION; ANGINA PECTORIS; ANGIOGENESIS; ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; BLOOD VESSEL TONE; CARDIAC GRAFT REJECTION; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CATHETER ABLATION; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DRUG COST; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; EDEMA; ENDOTHELIUM INJURY; ESSENTIAL HYPERTENSION; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GRAFT FAILURE; GRAFT REJECTION; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPOTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY INJURY; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; QT PROLONGATION; REPERFUSION INJURY; RESTENOSIS; RETINOPATHY; REVIEW; SOMATIC GENE THERAPY; TRANSLUMINAL CORONARY ANGIOPLASTY; TUMOR VASCULARIZATION; VEIN GRAFT DISEASE; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CARDIOVASCULAR DISEASES; GENE SILENCING; GENE TARGETING; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HUMANS;

ANIMALIA;

EID: 18844421599     PISSN: 14714914     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molmed.2005.03.008     Document Type: Review

References (101)

1. E.G. Nabel Cardiovascular disease N. Engl. J. Med. 349 2003 60 72
2. National Heart, Lung and Blood Institute (2003) NHLBI Morbidity and Mortality Chartbook 2002. National Heart, Lung and Blood Institute (http://www.americanheart.org)
3. C. Mah Virus-based gene delivery systems Clin. Pharmacokinet. 41 2002 901 911
4. T. Niidome, and L. Huang Gene therapy progress and prospects: non-viral vectors Gene Ther. 9 2002 1647 1652
5. L.G. Melo Gene and cell-based therapies for heart disease FASEB J. 18 2004 648 663
6. R. Morishita In vivo transfection of cis element 'decoy' against nuclear factor κB binding sites prevents myocardial infarction Nat. Med. 3 1997 894 899
7. L.G. Melo Molecular and cell-based therapies for protection, rescue, and repair of ischemic myocardium: reasons for cautious optimism Circulation 109 2004 2386 2393
8. N. Chirmule Immune responses to adenovirus and adeno associated virus in humans Gene Ther. 6 1999 1574 1583
9. A.S. Pachori Hypoxia-regulated therapeutic gene as a preemptive treatment strategy against ischemia/reperfusion tissue injury Proc. Natl. Acad. Sci. U. S. A. 101 2004 12282 12287
10. S.A. Nicklin, and A.H. Baker Tropism-modified adenoviral and adeno-associated viral vectors for gene therapy Curr. Gene Ther. 2 2002 273 293
11. L.G. Melo Endothelium targeted gene and cell-based therapies for cardiovascular disease Arterioscler. Thromb. Vasc. Biol. 24 2004 1761 1774
12. L.J. Feldman, and G. Steg Optimal techniques for arterial gene transfer Cardiovasc. Res. 35 1997 391 404
13. C.J. Panetta A tissue-engineered stent for cell-based vascular gene transfer Hum. Gene Ther. 13 2002 433 441
14. D.H. Walter Local gene transfer of phVEGF-2 plasmid by gene eluting stents: an alternative strategy for inhibition of restenosis Circulation 110 2004 36 45
15. Johnson, T.W. et al. (2005). Stent-based delivery of tissue inhibitor of metalloproteinase-3 adenovirus inhibits neointimal formation in porcine coronary arteries. Arterioscler. Thromb. Vasc. Biol. 10.1161/01.ATV.0000157582.33180.a9 (www.atvb.ahajournals.org)
16. B.D. Klugherz Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus Hum. Gene Ther. 13 2002 443 454
17. F. Sharif Current status of catheter- and stent-based gene therapy Cardiovasc. Res. 64 2004 208 216
18. J.M. Isner Myocardial gene therapy Nature 415 2002 234 239
19. C. Sylvein Catheter-based transendocardial myocardial gene transfer J. Interv. Cardiol. 15 2002 7 13
20. M.J. Mann, and V.J. Dzau Therapeutic applications of transcription factor decoy oligonucleotides J. Clin. Invest. 106 2000 1071 1075
21. C.A. Stein The experimental use of antisense oligonucleotides: a guide for the perplexed J. Clin. Invest. 108 2001 641 644
22. J.A. Doudna, and T.R. Cech The chemical repertoire of natural ribozymes Nature 418 2002 222 228
23. G.J. Hannon RNA interference Nature 418 2002 244 251
24. R.R. White Developing aptamers into therapeutics J. Clin. Invest. 106 2000 929 934
25. K.F. Lin Prolonged reduction of high blood pressure with human nitric oxide synthase delivery Hypertension 30 1997 307 313
26. K.F. Lin Atrial natriuretic peptide gene delivery attenuates hypertension, cardiac hypertrophy and renal injury in salt-sensitive rats Hum. Gene Ther. 9 1998 1429 1438
27. E. Dobrzynski Adrenomedullin gene delivery attenuates hypertension, cardiac remodeling and renal injury in deoxycorticosterone acetate salt hypertensive rats Hypertension 36 2000 995 1001
28. H. Yoshida Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion Hypertension 35 2000 25 31
29. X. Tang Intravenous angiotensinogen antisense in AAV-based vector decreases hypertension Am. J. Physiol. 277 1999 H2392 H2399
30. H. Wang Sustained inhibition of angiotensin I converting enzyme (ACE) expression and long-term antihypertensive action by virally mediated delivery of ACE antisense cDNA Circ. Res. 85 1999 614 622
31. M.J. Katovich Reversal of hypertension by angiotensin II type I receptor antisense gene therapy in the adult SHR rat Am. J. Physiol. 277 1999 H1260 H1264
32. Y.C. Zhang New β-blocker: prolonged reduction in high blood pressure with β1 antisense oligodeoxynucleotides Hypertension 35 2000 219 224
33. R.D. Braun-Dullaeus Cell cycle progression. New therapeutic target for vascular proliferative disease Circulation 98 1998 82 89
34. A.Y. Kim Early loss of thrombomodulin expresson impairs vein graft thromboresistance: implications for vein graft resistance Circ. Res. 90 2002 205 212
35. P. Zoldhelyi Thromboresistance of balloon-injured porcine carotid arteries after local gene transfer of human tissue factor pathway inhibitor Circulation 101 2000 289 295
36. K.P. Rentrop Thrombi in acute coronary syndromes. Revised and revisited Circulation 101 2000 1619 1626
37. L.J. Feldman, and J.M. Isner Gene therapy for vulnerable plaque J. Am. Coll. Cardiol. 26 1995 826 833
38. R.K. Tangirala Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-1 in mice Circulation 100 1999 1816 1822
39. S. Inoue Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice Circulation 106 2002 2700 2706
40. H.E. von der Leyen, and V.J. Dzau Therapeutic potential of nitric oxide synthase gene manipulation Circulation 103 2001 2760 2765
41. M.T. Gewaltig, and G. Kojda Vasoprotection by nitric oxide: mechanisms and therapeutic potential Cardiovasc. Res. 55 2002 250 260
42. H. Qian Nitric oxide synthase gene therapy rapidly reduces molecule expression and inflammatory cell infiltration in carotid artery of cholesterol-fed rabbits Circulation 99 1999 2979 2982
43. S.H. Juan Adenovirus-mediated heme oxygenase-1 gene transfer inhibits the development of atherosclerosis in apolipoprotein E-deficient mice Circulation 104 2001 1519 1525
44. M. Zanetti Gene transfer of manganese superoxide dismutase reverses vascular dysfunction in the absence but not in the presence of atherosclerotic plaque Hum. Gene Ther. 12 2001 1407 1416
45. M. Grossman A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia Nat. Med. 1 1995 1148 1154
46. V.J. Dzau Vascular proliferation and atherosclerosis: new perspectives and therapeutic strategies Nat. Med. 8 2002 1249 1256
47. H.E. Von der Leyen Gene therapy inhibiting neointimal vascular lesion: in vivo transfer of endothelial cell nitric oxide synthase gene Proc. Natl. Acad. Sci. U. S. A. 92 1995 1137 1141
48. E. Tzeng Vascular gene transfer of the human inducible nitric oxide synthase: characterization of activity and effects of myointimal hyperplasia Mol. Med. 2 1996 211 215
49. R. Morishita Single intraluminal delivery of antisense cdc2 kinase and proliferating cell nuclear antigen oligonucleotides results in chronic inhibition of neointimal hyperplasia Proc. Natl. Acad. Sci. U. S. A. 90 1993 8474 8478
50. M.J. Mann Genetic engineering of vein grafts resistant to atherosclerosis Proc. Natl. Acad. Sci. U. S. A. 92 1995 4502 4506
51. M.J. Mann Cell cycle inhibition preserves endothelial function in genetically engineered rabbit vein grafts J. Clin. Invest. 99 1997 1295 1301
52. R. Morishita A gene therapy strategy using a transcription factor decoy of the E2F binding site inhibits smooth muscle proliferation in vivo Proc. Natl. Acad. Sci. U. S. A. 92 1995 5855 5859
53. L.G. Melo Gene therapy strategy for long term myocardial protection using adeno-associated virus-mediated delivery of heme oxygenase gene Circulation 105 2002 602 607
54. L.G. Melo Preemptive gene therapy by AAV-mediated delivery of heme oxygenase-1 results in long-term normalization of left ventricular function and chamber dimensions Circulation 108 Suppl. IV 2003 IV 144
55. R.S. Agrawal Pre-emptive gene therapy using recombinant adeno-associated virus delivery of extracellular superoxide dismutase protects heart against ischemic reperfusion injury, improves ventricular function and prolongs survival Gene Ther. 11 2004 962 969
56. Y.Z. Woo Recombinant adenovirus-mediated cardiac gene transfer of superoxide dismutase and catalase attenuates postischemic contractile dysfunction Circulation 98 Suppl. 1998 II255 II260
57. H.L. Zhu Blocking free radical production via adenoviral gene transfer decreases cardiac ischemia-reperfusion injury Mol. Ther. 2 2000 470 475
58. T. Yoshida Transgenic mice overespressing glutathione peroxidase are resistant to myocardial reperfusion injury J. Mol. Cell. Cardiol. 28 1996 1759 1767
59. K. Suzuki In vivo gene transfer of heat shock protein 70 enhances myocardial tolerance to ischemia-reperfusion injury in rat J. Clin. Invest. 99 1997 1645 1650
60. S. Chatterjee Viral gene transfer of the antiapoptotic factor Bcl-2 protects against chronic ischemic heart failure Circulation 106 Suppl. 2002 I212 I217
61. T. Matsui Akt activation preserves cardiac function and prevents injury after transient cardiac ischemia in vivo Circulation 104 2001 330 335
62. R. Brauner Intracoronary adenovirus-mediated transfer of immunosuppressive cytokine genes prolongs allograft survival J. Thorac. Cardiovasc. Surg. 114 1997 923 933
63. C.A. Mack Biological bypass with the use of adenovirus-mediated transfer of the complementary deoxyribonucleic acid for vascular endothelial growth factor 121 improves myocardial perfusion and function in the ischemic porcine heart J. Thorac. Cardiovasc. Surg. 115 1998 168 177
64. 121 cDNA to individuals with clinically significant severe coronary artery disease Circulation 100 1999 468 474
65. J.F. Symes Gene therapy with vascular endothelial growth factor for inoperable coronary artery disease Ann. Thorac. Surg. 68 1999 830 837
66. F.J. Giordano Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in ischemic region of the heart Nat. Med. 2 1996 534 539
67. 165 as sole therapy for myocardial ischemia Circulation 98 1998 2800 2804
68. P.R. Vale Randomized, single-blind, placebo-controlled pilot study of catheter-based myocardial gene transfer for therapeutic angiogenesis using left ventricular electromechanical mapping in patients with chronic myocardial ischemia Circulation 103 2001 2138 2143
69. D.W. Losordo Phase 1/2 placebo-controlled, double-blind, dose escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia Circulation 105 2002 2012 2018
70. I. Ahmet Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart Ann. Thorac. Surg. 75 2003 1283 1287
71. H. Ueda Gene transfection of hepatocyte growth factor attenuates reperfusion injury in the heart Ann. Thorac. Surg. 67 1999 1726 1731
72. Y. Li Post-infarction treatment with and adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice Circulation 107 2003 2499 2506
73. Z. Yang Cardiac overexpression of A1-adenosine receptor protects intact mice against myocardial infarction Am. J. Physiol. 282 2002 H949 H955
74. R.J. Hajjar Prospects for gene therapy for heart failure Circ. Res. 86 2000 616 621
75. 2-adrenergic receptor in the heart, prospects for molecular ventricular assistance Circulation 101 2000 408 414
76. B.G. Bruneau Transcriptional regulation of vertebrate cardiac morphogenesis Circ. Res. 90 2002 509 519
77. T. Kawada Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy, Amelioration of morphological findings, sarcolemmal permeability, cardiac performance and the prognosis of TO-2 hamsters Proc. Natl. Acad. Sci. U. S. A. 99 2002 901 906
78. J.K. Donahue Focal modification of electrical conduction in the heart by viral gene transfer Nat. Med. 6 2000 1395 1398
79. H.B. Nuss Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes J. Clin. Invest. 103 1999 889 896
80. V. Jayasankar Gene transfer of hepatocyte growth factor attenuates postinfarction heart failure Circulation 108 Suppl. 1 2003 II230 II236
81. Y. Taniyama Angiogenesis and antifibrotic action by hepatocyte growth factor in cardiomyopathy Hypertension 40 2002 47 53
82. H. Su Adeno-associated viral vector delivers cardiac specific and hypoxia inducible VEGF expression in ischemic mouse hearts Proc. Natl. Acad. Sci. U. S. A. 101 2004 16280 16285
83. E.J. Rebar Induction of angiogenesis in a mouse model using engineered transcription factors Nat. Med. 8 2002 1427 1432
84. S.Y. Herttuala, and K. Alitalo Gene transfer as a tool to induce therapeutic vascular growth Nat. Med. 9 2003 694 700
85. J.A. Towbin, and N.E. Bowles The failing heart Nature 415 2002 227 233
86. 2-adrenergic receptor gene delivery J. Clin. Invest. 104 1999 21 29
87. S.A. Akhter Restoration of β-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer Proc. Natl. Acad. Sci. U. S. A. 94 1997 12100 12105
88. 2+-ATPase in a rat model of heart failure Circulation 104 2001 1424 1429
89. F. Del Monte Restoration of contractile function in isolated cardiomyocytes from failing human hearts by gene transfer of SERCA2a Circulation 100 1999 2308 2311
90. A. Baartscheer Adenovirus gene transfer of SERCA in heart failure. A promising therapeutic approach? Cardiovasc. Res. 49 2001 249 252
91. J.R. Balser Inherited sodium channelopathies: models for acquired arrhythmias? Am. J. Physiol. Heart Circ. Physiol. 282 2002 H1175 H1180
92. A. Bauer Inhibitory G protein overexpression provides physiologically relevant heart rate control in persistent atrial fibrillation Circulation 110 2004 3115 3120
93. U.C. Hoppe Distinct gene-specific mechanisms of arrhythmia revealed by cardiac gene transfer of two long QT disease genes, HERG and KCNE1 Proc. Natl. Acad. Sci. U. S. A. 98 2001 5335 5340
94. I.L. Ennis Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility J. Clin. Invest. 109 2002 393 400
95. M.L. Edelstein Gene therapy clinical trials worldwide 1989-2002 - an overview J. Gene Med. 6 2004 597 602
96. C.L. Grines Angiogenic gene therapy (AGENT) trial in patients with stable angina pectoris Circulation 105 2002 1291 1297
97. R. Morishita Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral artery disease Hypertension 44 2004 203 209
98. M.J. Mann Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: The PREVENT single-centre, randomized, controlled trial Lancet 354 1999 1493 1498
99. M. McCarthy Molecular decoy may keep bypass grafts open Lancet 358 2001 1703
100. N.C. Lai Intracoronary adenovirus encoding adenylyl cyclase VI increases left ventricular function in heart failure Circulation 110 2004 330 336
101. N.C. Lai Intracoronary delivery of adenovirus encoding adenylyl cyclase VI increases left ventricular function and cAMP-generating capacity Circulation 102 2000 2396 2401